Related references
Note: Only part of the references are listed.Evolutionary conservation and positive selection of influenza A nucleoprotein CTL epitopes for universal vaccination
Michael C. McGee et al.
JOURNAL OF MEDICAL VIROLOGY (2022)
Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway
Meiying Li et al.
VIROLOGY JOURNAL (2022)
Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort
Hanna Kann et al.
JOURNAL OF INFECTIOUS DISEASES (2021)
Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity
Sarah L. Caddy et al.
EMBO JOURNAL (2021)
The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat
David C. Montefiori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials
Filipe Colaro Mariz et al.
LANCET INFECTIOUS DISEASES (2021)
Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects
Dhuha H. Nawab
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)
Mutation Profiles, Glycosylation Site Distribution and Codon Usage Bias of Human Papillomavirus Type 16
Wei Liu et al.
VIRUSES-BASEL (2021)
Immunodominance of Epitopes and Protective Efficacy of HI Antigen Are Differentially Altered Using Different Adjuvants in a Mouse Model of Staphylococcus aureus Bacteremia
Zhifu Chen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells
Evan D. Rossignol et al.
CELL REPORTS (2021)
Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination
Carolyn M. Boudreau et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
HPV-Specific Systemic Antibody Responses and Memory B Cells are Independently Maintained up to 6 Years and in a Vaccine-Specific Manner Following Immunization with Cervarix and Gardasil in Adolescent and Young Adult Women in Vaccination Programs in Italy
Francesco Nicoli et al.
VACCINES (2020)
Human Papillomavirus Vaccines: An Updated Review
Liqin Cheng et al.
VACCINES (2020)
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques
Neeltje van Doremalen et al.
NATURE (2020)
HPV Vaccination and the Risk of Invasive Cervical Cancer
Jiayao Lei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries
Susanne K. Kjaer et al.
ECLINICALMEDICINE (2020)
Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses
Bronwyn M. Gunn et al.
JOURNAL OF INFECTIOUS DISEASES (2020)
Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort
Hanna Artemchuk et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Role of IgG3 in Infectious Diseases
Timon Damelang et al.
TRENDS IN IMMUNOLOGY (2019)
A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis
Christina B. Karsten et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2019)
A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation
Stephanie Fischinger et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2019)
A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years
Tino F. Schwarz et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination-Review of Current Perspectives
Chee Kai Chan et al.
JOURNAL OF ONCOLOGY (2019)
Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine
Carolyn M. Boudreau et al.
FRONTIERS IN IMMUNOLOGY (2019)
The Coming Age of Insect Cells for Manufacturing and Development of Protein Therapeutics
Christine M. Yee et al.
INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH (2018)
Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus
Joshua W. Wang et al.
JOURNAL OF VIROLOGY (2018)
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Giuseppe Del Giudice et al.
SEMINARS IN IMMUNOLOGY (2018)
Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study
Rengaswamy Sankaranarayanan et al.
VACCINE (2018)
Explanations for the high potency of HPV prophylactic vaccines
John Schiller et al.
VACCINE (2018)
Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development
Ligia A. Pinto et al.
VACCINE (2018)
Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs
Lauri E. Markowitz et al.
VACCINE (2018)
Systems analysis of human vaccine adjuvants
Ali M. Harandi
SEMINARS IN IMMUNOLOGY (2018)
AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
Surender Khurana et al.
NPJ VACCINES (2018)
Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis
Kathryn M. Frietze et al.
EXPERT REVIEW OF VACCINES (2018)
Comparison of Yeasts as Hosts for Recombinant Protein Production
Antonio Milton Vieira Gomes et al.
MICROORGANISMS (2018)
HPV vaccines - A review of the first decade
Diane M. Harper et al.
GYNECOLOGIC ONCOLOGY (2017)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Frederick Arce Vargas et al.
IMMUNITY (2017)
Effect of Chitosan and Liposome Nanoparticles as Adjuvant Codelivery on the Immunoglobulin G Subclass Distribution in a Mouse Model
Agus Haryono et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Adjuvant-Mediated Epitope Specificity and Enhanced Neutralizing Activity of Antibodies Targeting Dengue Virus Envelope Protein
Denicar Lina Nascimento Fabris Maeda et al.
FRONTIERS IN IMMUNOLOGY (2017)
Glutaraldehyde Cross-linking of HIV-1 Env Trimers Skews the Antibody Subclass Response in Mice
Martina Soldemo et al.
FRONTIERS IN IMMUNOLOGY (2017)
Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo
Joshua A. Horwitz et al.
CELL (2017)
Cross-protection of the Bivalent Human Papillomavirus (HPV) Vaccine Against Variants of Genetically Related High-Risk HPV Infections
Ariana Harari et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study
Barbara Romanowski et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Coordinated Neutralization and Immune Activation by the Cytosolic Antibody Receptor TRIM21
Adam J. Fletcher et al.
JOURNAL OF VIROLOGY (2016)
Modulating Antibody Functionality in Infectious Disease and Vaccination
Bronwyn M. Gunn et al.
TRENDS IN MOLECULAR MEDICINE (2016)
A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice
Raffael Nachbagauer et al.
NPJ VACCINES (2016)
Surveillance for Intracellular Antibody by Cytosolic Fc Receptor TRIM21
William A. McEwan
ANTIBODIES (2016)
Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology
Amy W. Chung et al.
CELL (2015)
Evaluation of the Long-Term Anti-Human Papillomavirus 6 ( HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine
Mari Nygard et al.
CLINICAL AND VACCINE IMMUNOLOGY (2015)
Gardasil 9 joins the fight against cervix cancer
Jack Cuzick
EXPERT REVIEW OF VACCINES (2015)
TRIM21: a cytosolic Fc receptor with broad antibody isotype specificity
Stian Foss et al.
IMMUNOLOGICAL REVIEWS (2015)
A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
E. A. Joura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans
Ka Yan Chung et al.
VACCINE (2015)
Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine
Anna Godi et al.
PLOS ONE (2015)
Cell-mediated immune response: a clinical review of the therapeutic potential of human papillomavirus vaccination
Sonja Izquierdo Meyer et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA (2014)
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
S. Rachel Skinner et al.
LANCET (2014)
Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials
Pierre Van Damme et al.
VACCINE (2014)
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study
Mark H. Einstein et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus
Douglas M. Herrin et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
Paulo S. Naud et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
Mark H. Einstein et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Contribution of human FcγRs to disease with evidence from human polymorpnisms and transgenic animal studies
Caitlin Gillis et al.
FRONTIERS IN IMMUNOLOGY (2014)
HPV vaccine cross-protection: Highlights on additional clinical benefit
Rosa De Vincenzo et al.
GYNECOLOGIC ONCOLOGY (2013)
Cross protection against HPV might prevent type replacement
Inge Verdenius et al.
LANCET INFECTIOUS DISEASES (2013)
Diseases associated with human papillomavirus infection
Heather A. Cubie
VIROLOGY (2013)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen et al.
LANCET ONCOLOGY (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines
John T. Schiller et al.
VACCINE (2012)
Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine For the Prevention of Genital Warts in Males
Karly P. Garnock-Jones et al.
DRUGS (2011)
A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
Margaret E. Ackerman et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Functional Characteristics of the High Affinity IgG Receptor, FcγRI
Cees E. van der Poel et al.
JOURNAL OF IMMUNOLOGY (2011)
Vaccine Adjuvants: Putting Innate Immunity to Work
Robert L. Coffman et al.
IMMUNITY (2010)
Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
Young-Jae Kim et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2010)
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women
Nubia Munoz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Comparison of the immunogenicity and safety of Cervarix™ and Gardasil® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years
Mark H. Einstein et al.
HUMAN VACCINES (2009)
AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
Arnaud M. Didierlaurent et al.
JOURNAL OF IMMUNOLOGY (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Fc gamma receptors as regulators of immune responses
Falk Nimmerjahn et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Protein N-glycosylation in the baculovirus-insect cell system
Xianzong Shi et al.
CURRENT DRUG TARGETS (2007)
Regularization and variable selection via the elastic net
H Zou et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY (2005)
Partial least squares for discrimination
M Barker et al.
JOURNAL OF CHEMOMETRICS (2003)
Share Paper
